MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Merck & Co Inc.

Geschlossen

BrancheGesundheitswesen

86.47 -0.15

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

86.26

Max

88.77

Schlüsselkennzahlen

By Trading Economics

Einkommen

583M

3.7B

Verkäufe

-1B

16B

KGV

Branchendurchschnitt

13.318

63.778

EPS

1.72

Dividendenrendite

3.61

Gewinnspanne

23.963

Angestellte

73,000

EBITDA

1.3B

6.9B

Empfehlungen

By TipRanks

Empfehlungen

Buy

12-Monats-Prognose

+29.19% upside

Dividenden

By Dow Jones

Dividendenrendite

Branchendurchschnitt

3.61%

2.39%

Nächstes Ergebnis

24. Apr. 2025

Nächste Dividendenausschüttung

7. Apr. 2025

Nächstes Ex-Dividendendatum

16. Juni 2025

Marktstatistiken

By TradingEconomics

Marktkapitalisierung

-26B

227B

Vorheriger Eröffnungskurs

86.62

Vorheriger Schlusskurs

86.47

Nachrichtenstimmung

By Acuity

34%

66%

99 / 386 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Bearish Evidence

Merck & Co Inc. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Ähnliche Nachrichten

4. Feb. 2025, 12:33 UTC

Ergebnisse

Merck 4Q Earnings Rise; 2025 Outlook Hits Shares -- Update

4. Feb. 2025, 11:57 UTC

Ergebnisse

Merck 4Q Sales Increase Results in Swing to Profit

24. März 2025, 05:00 UTC

Ergebnisse
Akquisitionen, Fusionen, Übernahmen

Chipotle and 4 More Buyback Stocks for a Down Market -- Barrons.com

5. März 2025, 19:42 UTC

Top News

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- Update

5. März 2025, 10:30 UTC

Top News

New Version of Merck's Blockbuster Cancer Drug Threatened by Patent Battle -- WSJ

5. Feb. 2025, 12:00 UTC

Top News

Merck Is Suffering From a Classic Pharma Problem -- Heard on the Street -- WSJ

4. Feb. 2025, 14:48 UTC

Ergebnisse

Merck Stock Plummets 10% As Gardasil Dynamics, 2025 Guidance Weigh On Shares -- IBD

4. Feb. 2025, 11:51 UTC

Ergebnisse

Merck's Soft Guidance Offsets Better-Than-Expected Fourth-Quarter Earnings -- MarketWatch

4. Feb. 2025, 11:50 UTC

Ergebnisse

Merck Stock Tumbles on Weak Guidance and Gardasil Sales Slump -- Barrons.com

4. Feb. 2025, 11:31 UTC

Ergebnisse

Merck 4Q Gardasil/Gardasil 9 Sales Down 17% >MRK

4. Feb. 2025, 11:31 UTC

Ergebnisse

Merck 4Q Gardasil/Gardasil 9 Sales $1.55B >MRK

4. Feb. 2025, 11:31 UTC

Ergebnisse

Merck 4Q Januvia/Janumet Sales Down 38% >MRK

4. Feb. 2025, 11:31 UTC

Ergebnisse

Merck 4Q Januvia/Janumet Sales $487M >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck 4Q Keytruda Sales Up 19% >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck 4Q Keytruda Sales $7.84B >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck 4Q Pharmaceutical Sales Up 7% >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck 4Q Pharmaceutical Sales $14.04B >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck Sees FY Adj EPS $8.88-Adj EPS $9.03 >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck: Anticipate Strong Growth in Back Half of 2025, as Well as in Both 2026 and 2027 >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck Sees FY Rev $64.1B-$65.6B >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck: Believe Temporary Pause Will Facilitate a More Rapid Reduction of Excess Inventory >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck: Expect Strength in Oncology and Contributions From Ongoing and New Launches of Important Products in Both Human and Animal Health Businesses to More Than Offset GARDASIL Headwind >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck 4Q Adj EPS $1.72 >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck: Gardasil Market Dynamics in China Do Not in Any Way Diminish the Confidence Co. Has in the Business >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck 4Q Net $3.74B >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck: Excluding Sales of Gardasil in China in Both 2024 and 2025, Expect Strong 2025 Growth Between 7%-9% (Ex-FX) Driven by Continued Strength in Oncology and Animal Health as Well as Contributions From New Product Launches >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck: Sales Outlook Reflects Reassessment of Market for Gardasil/Gardasil 9 in China and Decision to Temporarily Pause Shipments Until at Least Mid-Year >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck Sees FY25 Sales $64.1B-$65.6B >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck: Decline in 4Q Januvia/Janumet Sales Primarily Due to Lower Pricing in U.S., and Ongoing Generic Competition in Many International Markets and Supply Constraints in China >MRK

4. Feb. 2025, 11:30 UTC

Ergebnisse

Merck 4Q Winrevair Sales $200M >MRK

Peer-Vergleich

Kursveränderung

Merck & Co Inc. Prognose

Kursziel

By TipRanks

29.19% Vorteil

12-Monats-Prognose

Durchschnitt 111.88 USD  29.19%

Hoch 138 USD

Tief 95 USD

Basierend auf 17 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Merck & Co Inc. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Buy

17 ratings

11

Buy

6

Halten

0

Sell

Technischer Score

By Trading Central

N/A / 93.07Unterstützung & Widerstand

Kurzfristig

Bearish Evidence

Mittelfristig

Bullish Evidence

Langfristig

Bearish Evidence

Stimmung

By Acuity

99 / 386 Ranking in Gesundheitswesen

Nachrichtenstimmung

Bullische Evidenz

Volatilität

Unterdurchschnittlich

Nachrichtenvolumen (RCV)

Überdurchschnittlich

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

$

Über Merck & Co Inc.

Merck & Co., Inc. operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names. The Animal Health segment discovers, develops, manufactures, and markets veterinary pharmaceuticals, vaccines, and health management solutions and services, as well as digitally connected identification, traceability, and monitoring products. vIt has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates, which include patritumab deruxtecan, ifinatamab deruxtecan, and raludotatug deruxtecan for the treatment of multiple solid tumors both as monotherapy and/or in combination with other treatments; and AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types, and Koselugo for multiple indications. It also has licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova. The company also has a collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. was founded in 1891 and is headquartered in Rahway, New Jersey.